The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in response to neoadjuvant sequential therapy of combination nab-paclitaxel and gemcitabine followed by stereotactic body radiotherapy (SBRT).
This is a non-interventional, observational study. Multiple myeloma will be treated as per standard therapy and/or with medicinal product prescribed by the treating healthcare provider based upon his/her clinical judgment.
This is a study to test an over the counter agent to decrease the incidence and severity of mucositis for patients undergoing radiation therapy or radiation therapy and chemotherapy for head and neck cancer
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IV squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
This randomized phase II trial is studying radiation therapy with or without chemotherapy to see how well it works in treating patients with high-risk malignant salivary gland tumors that have been removed by surgery.
This is a phase 1b study to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and recommended phase 2 dose of APTO-253 HCl in patients with relapsed or refractory hematologic malignancies.
This is an open-label, multi-center, randomized, Phase 3 study designed to compare the efficacy and safety of AM0010 in combination with FOLFOX versus FOLFOX alone in patients with metastatic adenocarcinoma of the pancreas who have progressed on one prior gemcitabine containing regimen.
The purpose of this study is to assess the safety and tolerability of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Monoclonal Antibody, and REGN2810, an Anti-Programmed Death-1 Monoclonal Antibody, in patients with B-cell malignancies.
The purpose of this study is to evaluate the safety, pharmacokinetics and efficacy of Venetoclax as a single-agent and in combination with Azacitidine in subjects with high-risk myelodysplastic syndromes after hypomethylating agent-failure
